Viking Therapeutics begins study of oral VK2735 for obesity

​

Viking Therapeutics has commenced the second part of a clinical trial evaluating oral maintenance dosing schedules of its dual GLP-1 and GIP receptor agonist, VK2735, in adults with obesity.

The post Viking Therapeutics begins study of oral VK2735 for obesity appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.